At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
Exemestanedrug
Likely dose
Exemestane 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Exemestane in Previously Treated Post-Menopausal Women With Advanced Non-Small Cell Lung Cancer
Masonic Cancer Center, University of Minnesota·interventional·Posted Jan 28, 2016·Updated May 31, 2023
In Brief
A Phase 2 clinical trial evaluating Exemestane for Non-Small Cell Lung Cancer. Completed, enrolled 6 participants across 18 sites.
Detailed Summary
This is a phase II therapeutic study of adding exemestane therapy in post-menopausal women with advanced non-small cell lung cancer (NSCLC) who are progressing while on treatment with an immune checkpoint antibody (pembrolizumab, atezolizumab, or nivolumab).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartSep 2018
Primary CompletionFeb 2022
TodayJul 2026
First PostedJan 28, 2016
Enrollment StartSep 27, 2018
Primary CompletionFeb 28, 2022
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 10.4 years ago
Interventions
Exemestanedrug
One 25 mg tablet once daily for a minimum of 6 weeks